SCHEDULE: Armistice Capital Boosts Macrogenics Stake to 9.45%
Beneficial Ownership Report
Armistice Capital and Steven Boyd report a 9.45% beneficial ownership stake in Macrogenics Inc., holding 5,960,000 shares of common stock.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the Reporting Persons, have filed an Amendment No. 5 to Schedule 13G.
- The filing reports beneficial ownership of 5,960,000 shares of Macrogenics Inc. Common Stock, par value $0.01 per share.
- This represents 9.45% of the outstanding class of securities.
- The percentage is based on 63,090,323 shares outstanding as of May 9, 2025, as reported in Macrogenics Inc.'s Form 10-Q filed on May 13, 2025.
- Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
- Both reporting persons share voting and dispositive power over all 5,960,000 shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose or with the effect of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a routine Schedule 13G filing reporting a passive ownership stake. It is neutral in terms of company performance or operational news, but indicates continued significant institutional interest in Macrogenics Inc.
Positives
- A significant institutional investor, Armistice Capital, maintains a substantial stake (9.45%) in Macrogenics Inc., which can be interpreted as a continued vote of confidence in the company's long-term prospects.
Risks
- The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating concerns about potential hostile takeovers or activist campaigns.
Future Outlook
This filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.
Industry Context
This filing is a routine disclosure of a significant ownership stake by an institutional investor. It does not provide specific insights into broader industry trends or competitive dynamics, but rather reflects an investment decision within the biotechnology or pharmaceutical sector, where Macrogenics Inc. operates.
Stakeholder Impact
- Shareholders may view the continued significant ownership by Armistice Capital as a positive signal, indicating sustained institutional confidence in Macrogenics Inc.
Key Dates
| Date | Description |
|---|---|
| 05/09/2025 | Date as of which 63,090,323 shares of Macrogenics Inc. Common Stock were reported outstanding in the Issuer's Form 10-Q. |
| 05/13/2025 | Date Macrogenics Inc. filed its Form 10-Q with the SEC, reporting shares outstanding. |
| 06/30/2025 | Date of event which requires the filing of this Schedule 13G statement. |
| 08/14/2025 | Date the Schedule 13G Amendment No. 5 was signed and filed. |
Keywords
Macrogenics, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.